Antineoplastic Agents

Resveratrol is a natural antioxidant, which can reduce blood viscosity, inhibit platelet coagulation and vasodilation, keep blood smooth, prevent the occurrence and development of cancer, and has the preventive and therapeutic effects of anti atherosclerosis, coronary heart disease, ischemic heart disease and hyperlipidemia. Tumor suppressor also has estrogen like effect and can be used to treat breast cancer and other diseases. It can delay aging and prevent cancer. It is high in red grape skin, red wine and grape juice. Studies have shown that the integrity of the chromosome will be destroyed with human aging, and resveratrol can activate a protein to repair the health of the chromosome, so as to play a role in delaying aging. In conclusion, resveratrol has antioxidant, anti-inflammatory, antithrombotic, anti-cancer, anti-cancer, anti hyperlipidemia, antibacterial and other activities.

Ola Pani is a chemotherapeutic agent for the treatment of recurrent or advanced ovarian cancer and metastatic breast cancer in patients with specific mutations and previous history of chemotherapy. Olapani is sold under the lynparza brand in the form of oral tablets and was originally designated as maintenance therapy or monotherapy for adult patients with recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer.

Fluticasone is an intramuscular injection developed by AstraZeneca. It was approved by the food and Drug Administration in April 2002 to treat estrogen receptor positive metastatic breast cancer in postmenopausal women whose disease is still deteriorating after anti estrogen therapy. Many breast cancer cells have estrogen receptor (ER), estrogen can stimulate the growth of such tumors. Fluvestrant is a "pure" estrogen receptor antagonist without partial estrogen like agonistic effect. It inhibits estrogen signal pathway by binding, blocking and down regulating er. It can competitively bind with ER. Its affinity with Er is close to estrogen, 100 times that of tamoxifen. It is the only anti estrogen drug that can be widely used in clinic after tamoxifen fails, Because the drug is endocrine therapy and will not cause common adverse reactions of chemotherapy, it has good patient compliance.

Abiraterone acetate (INN, USAN, BAN, JAN) (brand names Zytiga, Abiratas, Abretone, Abirapro) is a steroidal antiandrogen, specifically an androgen synthesis inhibitor, used in combination with prednisone in metastatic castration-resistant prostate cancer (previously called hormone-resistant or hormone-refractory prostate cancer) – i.e., prostate cancer not responding to androgen deprivation or treatment with androgen receptor antagonists. It is a prodrug to the active agent abiraterone, and is marketed by Janssen Biotech under the trade name Zytiga. In addition, Intas Pharmaceuticals markets the drug under the trade name Abiratas, Cadila Pharmaceuticals markets the drug as Abretone, and Glenmark Pharmaceuticals as Abirapro. Abiraterone acetate was approved by the United States Food and Drug Administration on April 28, 2011. The FDA press release made reference to a phase III clinical trial in which abiraterone use was associated with a median survival of 14.8 months versus 10.9 months with placebo; the study was stopped early because of the successful outcome.

Capecitabine, an antimetabolite fluoropyrimidine deoxynucleoside carbamate that can be converted to 5-FU in vivo, was developed by Roche under the trade name hiloda and is able to inhibit cell division and interfere with RNA and protein synthesis. For further treatment of paclitaxel and advanced primary or metastatic breast cancer including patients refractory to chemotherapeutic regimens with anthracyclines. It is mainly used for the treatment of advanced primary or metastatic breast, rectal, colon and gastric cancer.